1998
DOI: 10.1159/000040718
|View full text |Cite
|
Sign up to set email alerts
|

Use of Desmopressin for Prophylaxis of Surgical Bleeding in Factor XI-Deficient Patients

Abstract: Desmopressin represents a well-established treatment for patients with von Willebrand disease and mild hemophilia A [1, 2]. Recently, this drug has been used with success in two symptomatic factor XI (FXI)-deficient individuals before surgery [3]. We report herein our own experience with 2 patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0
3

Year Published

1999
1999
2018
2018

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 6 publications
0
7
0
3
Order By: Relevance
“…The successful use of DDAVP for the prevention of bleeding in a patient with a mild FXI defect undergoing a neurosurgery operation was reported by Bauduer and colleagues [22]. The largest experience in this field has been described by our group [23].…”
Section: Resultsmentioning
confidence: 93%
See 1 more Smart Citation
“…The successful use of DDAVP for the prevention of bleeding in a patient with a mild FXI defect undergoing a neurosurgery operation was reported by Bauduer and colleagues [22]. The largest experience in this field has been described by our group [23].…”
Section: Resultsmentioning
confidence: 93%
“…Only few case reports have been reported so far on the use of desmopressin for the treatment of bleeding or as surgical prophylaxis in patients with inherited deficiency of FXI [20][21][22][23][24][25][26][27]. Castaman and colleagues [21] reported about two patients with partial FXI deficiency and previous bleeding histories who received DDAVP infusions before carpal tunnel surgery and dental extraction.…”
Section: Resultsmentioning
confidence: 99%
“…Die Entlassung des Kindes in ambulante Betreuung erfolgte am 11. postoperativen Tag bei Wohlbefinden. [2,7,9,13,17,18].…”
Section: Laboruntersuchungenunclassified
“…Sie werden auch weiterhin empfohlen, jedoch vorzugsweise für jüngere Patienten mit schwerem Mangel [2,4]. Nachteile der Faktor-XI-Konzentrate sind neben den hohen Kosten Gerinnungsaktivierungen mit Erhöhungen von Prothrombinfragment 1 + 2, Fibrinopeptid A und TAT sowie manifeste Thrombosen, besonders bei älteren Patienten [4,9,11,16,19].…”
Section: Laboruntersuchungenunclassified
See 1 more Smart Citation